MB 301 - Must Bio
Alternative Names: MB-301 - Must BioLatest Information Update: 02 Aug 2023
At a glance
- Originator Must Bio
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunomodulators; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 13 Jul 2023 MB 301 - Must Bio is available for licensing as of 13 Jul 2023. http://mustbio.com/sub/sub04.php
- 13 Jul 2023 Early research in Cancer in South Korea (Parenteral), prior to July 2023 (Must Bio pipeline, July 2023)